Tommy Lai
WuXi AppTec (China) · 13 works · 793 citations · h-index 9
Top works
- Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition
- GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer
- Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)
- Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
- From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors
- Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies
- Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha
- Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927
- Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer
- Discovery of potent dihydro-oxazinoquinolinone inhibitors of GuaB for the treatment of tuberculosis
- Total Synthesis of Pedopeptin C
- CCDC 2167969: Experimental Crystal Structure Determination
- Abstract A20: A leukemic model of acquired resistance to BET inhibition reveals a role for CBP/EP300 bromodomains in the regulation of c-MYC expression